Imunon, Inc.

Good morning, everyone. My name is Jamie, and I will be your operator today. At this time, I would like to welcome you to Immunon's second quarter 2020 financial results conference call. All lines have been placed on mute to prevent any background noise. Following the speaker's prepared remarks, there will be a question and answer session. You may press star and then one on your touchstone telephones to ask a question at that time. Please keep in mind if you are using a speaker phone, you must release your mute function to allow the signal to reach our equipment. Again, that is star and then one to ask a question during the question and answer session. Please also note today's event is being recorded. At this time, I'd like to turn the floor over to Kim Golodets. Please go ahead.

Thank you, and good morning, everyone. This is Kim Golodets with LHA. Welcome to Immunon's second quarter 2024 financial results and business update conference call. During today's call, management will be making forward-looking statements regarding Immunon's expectations and projections about future events. In general, forward-looking statements can be identified by words such as expects, anticipates, believes, or other similar expressions. These statements are based on current expectations and are subject to a number of risks and uncertainties including those set forth in the company's periodic filings with the Securities and Exchange Commission. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. I also caution that the content of this conference call is accurate only as of the date of the live broadcast, August 14, 2024. Immunon undertakes no obligation to revise or update comments made during this call, except as required by law. With that said, I would like to turn the call over to Michael Tarduno, Immunon's executive chairman. Michael?

Thank you, Kim, and good morning, everyone. I just wanted to take the liberty to say a few words before turning the call over to Stacey Lindborg, our president and chief executive officer, and to David Gallero, who is our interim chief financial officer as we seek a permanent replacement for our retired CFO, Jeff Church. And just a point, following our prepared remarks, there will be time for questions. And this is your opportunity. We encourage you to, if you have a question, to use this time to ask us. We're happy to respond to your questions and concerns. On the fundamentals, I can report that your company is sound. The second quarter and recent weeks give testament to that. and to Dr. Lindborg's strategy and leadership. As you know, we recently reported long-awaited top-line data from our Phase II study of Immunon-001, our unique IL-12 candidate in ovarian cancer. These are women with very few options facing a standard of care that has seen very little change over the past 25 years. And given that, I can report that the results from our study, in a word, outstanding, unequivocally outstanding. In support of this remarkable outcome, Stacey has streamlined the company, refocused its attention, reduced expenses, and despite the challenging comparable deal terms that we've seen recently, closed on a truly investor-friendly financing in this tough, tough capital market. I am delighted with our company's progress over the past quarter, as I hope you are, and with the future promise that Immunon OO1 has for ovarian cancer patients. I'll also remind you that during the second quarter, Dr. Lindborg was appointed President and Chief Executive of Immunon. I'm sure that it was a difficult decision for her, as she left a similar position with a company that she very, very much believed in, to lead the development of our lead asset, Immunon 001, and to shape the company's strategy. I trust that you will agree with me that she has hit the ground running. So now it's my pleasure to turn the call over to Stacey.